Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Gross Margin (2016 - 2025)

Cytosorbents (CTSO) has disclosed Gross Margin for 14 consecutive years, with 70.27% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin rose 925.0% year-over-year to 70.27%, compared with a TTM value of 71.55% through Sep 2025, up 655.0%, and an annual FY2024 reading of 70.59%, down 3.0% over the prior year.
  • Gross Margin was 70.27% for Q3 2025 at Cytosorbents, down from 70.86% in the prior quarter.
  • Across five years, Gross Margin topped out at 77.46% in Q2 2021 and bottomed at 44.6% in Q3 2022.
  • Average Gross Margin over 5 years is 66.64%, with a median of 70.27% recorded in 2025.
  • The sharpest move saw Gross Margin plummeted -3017bps in 2022, then soared 1904bps in 2023.
  • Year by year, Gross Margin stood at 71.04% in 2021, then fell by -14bps to 61.31% in 2022, then fell by -8bps to 56.21% in 2023, then skyrocketed by 32bps to 74.0% in 2024, then decreased by -5bps to 70.27% in 2025.
  • Business Quant data shows Gross Margin for CTSO at 70.27% in Q3 2025, 70.86% in Q2 2025, and 71.13% in Q1 2025.